Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
Scandinavian Journal of Immunology
|
July 15, 2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells
M Peipp, D Wesch, H-H Oberg, et al.
Leukemia
|
October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity
C Kellner, D Hallack, P Glorius, et al.
Leukemia
|
June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
P Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunological Methods
|
July 16, 2011
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development
C Kellner, W K Bleeker, J J Lammerts van Bueren, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
Scandinavian Journal of Immunology
|
July 15, 2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells
M Peipp, D Wesch, H-H Oberg, et al.
Leukemia
|
October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity
C Kellner, D Hallack, P Glorius, et al.
Leukemia
|
June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
P Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunological Methods
|
July 16, 2011
Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development
C Kellner, W K Bleeker, J J Lammerts van Bueren, et al.
Page
of 5